Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rabies vaccine booster still effective after 5 years, study to confirm

NCT ID NCT07455318

Vaccine Sponsor: Institute of Tropical Medicine, Belgium Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study checks if a single rabies booster shot can still protect people who got their first rabies vaccine at least 5 years ago. About 561 healthy adults will get a booster, and researchers will measure their immune response after 7 days. The goal is to see if different initial vaccine schedules all provide long-lasting protection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 561 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. ≥ 18 to ≤ 60 years of age at time of inclusion 2. Willingness to provide written informed consent 3. Having received PrEP with a 21IM, 2²ID or 1²ID regimen at least 5 years before starting the study. For 21IM and 2²ID interval of 5 days to 56 days between the 2 visits is allowed. Exclusion Criteria: 1. Known allergy to one of the components of the vaccine. 2. Subjects, who received immunomodulating therapy within the last 3 months (12 weeks). Note: See Section 6.3 for detailed guidance on immunomodulating therapies. 3. Planned vaccination with any inactivated vaccine within 2 weeks before or after vaccination in the study or with any live attenuated vaccine within 1 month before or after each vaccination in the study. 4. Ongoing pregnancy or active child wish at the time of booster vaccination (D0). 5. Any other PrEP rabies vaccine schedule/vaccination than mentioned in the inclusion criteria. 6. Previous rabies (s)PEP 7. Inability or unwillingness to comply with study procedures, including protocol-defined visits, assessments, or interventions.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rabies (healthy volunteers) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rabies prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rabies (healthy volunteers)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire de Liège

    Liège, 4000, Belgium

  • Centrum voor vaccinologie (CEVAC)

    Ghent, 9000, Belgium

  • Clinical Trial Site Insitute of Tropical Medicine

    Antwerp, 2000, Belgium

  • Cliniques Universitaires de Saint Luc

    Brussels, 1200, Belgium

  • Military Hospital Queen Astrid

    Neder-Over-Heembeek, 1120, Belgium

  • UZ Brussel

    Jette, 1090, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.